D a t a s o u r c e s
Studies were identified by searching MED-LINE (1966 to 1999), EMBASE/Excerpta Medica (1988 to 1998), PsycLIT (1974 PsycLIT ( to 1997 , CINAHL (1982 CINAHL ( to 1999 , and the Cochrane Controlled Trials Register database; scanning the reference lists of identified articles; and contacting the manufacturers of SSRIs.
S t u d y s e l e c t i o n
Studies were selected if they were randomized, double-blind, placebo-controlled trials investigating SSRIs in the management of PMS.
D a t a e x t r a c t i o n
Data were independently extracted in duplicate on study design, patient characteristics, drug type and dose, outcome measures (primary outcome measure was reduction in overall PMS symptoms), and side effects.
M a i n r e s u l t s 15 studies met the selection criteria and involved 904 women (570 allocated to active treatment and 435 allocated to placebo, including 101 in crossover trials). The 2 most studied SSRIs were fluoxetine (7 trials) and sertraline (5 trials). Most of the trials presented continuous data; thus, an overall standardized mean difference was calculated by using a random-effects model. The overall standardized mean difference for reduction in PMS symptoms in favor of SSRIs was −1.1 (95% CI −1.4 to −0.8), which is equivalent to an odds ratio of 6.9 (CI 3.9 to 12.2). In 7 trials where data could be extracted for a comparison between physical and behavioral symptoms, SSRIs were found to be effective in treating both types with no statistically significant variance in the overall standardized mean differences. No difference in the effectiveness of SSRIs existed when comparing continuous and intermittent doses or between trials funded by pharmaceutical companies and those funded otherwise. Withdrawal from the studies because of side effects was 2.5 times greater (CI 1.6 to 3.7) in the SSRI group than in the placebo group.
C o n c l u s i o n
In patients with severe premenstrual syndrome, selective serotonin reuptake inhibitors reduce symptoms. 
C o m m e n t a r y
The well-done review by Dimmock and colleagues shows that SSRIs improve symptoms in PMS. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria for the severe variant of PMS-premenstrual dysphoric disorder-are stringent and require prospective confirmation of the symptoms and their unique occurrence during the luteal phase and disappearance during the follicular phase for 2 consecutive cycles. Depression may occur concomitantly. No accepted pathophysiologic abnormality exists, which means we have no diagnostic laboratory test for this difficult-to-define condition. It has, however, been shown that women with PMS exhibit an abnormal response to normal hormonal changes in contrast to those without PMS (1).
As the authors have shown in a previous review (2), other pharmacologic agents also work in PMS, which suggests that we try those with the lowest side-effect profile after carefully identifying patients for treatment. But it would not be appropriate to limit treatment to medication with these often severely distressed patients. Easily deployed nondrug interventions also work well. Cognitive behavioral treatment is effective in patients with medically unexplained symptoms (3). Furthermore, careful attention to the provider−patient relationship in a patient-centered atmosphere has equally welldocumented benefits, as recent reviews note (4, 5). Thus, one can best help symptomatic patients with a multidimensional intervention, one small part of which is an SSRI.
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